Fact CheckerSign in

NCT07739342Not yet recruiting

Evaluating the Occurrence of DKA in People With Type I Diabetes

Evaluating the Occurrence of DKA in People With Type 1 Diabetes

Source: ClinicalTrials.gov · Last updated 31 Jul 2026

Brief summary (registry, in English)

This study will evaluate the occurrences of Diabetes-related Ketoacidosis (DKA) in adult and pediatric individuals living with Type I diabetes while managing diabetes with Abbott's Continuous Monitoring Systems.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
1200 (estimated)
First submitted
28 Jul 2026
Start date
Sept 2026
Primary completion date
Dec 2027
Lead sponsor
Abbott Diabetes Care
NCT number
NCT07739342

What you commit to

  • Study type: Observational
  • Planned participants: 1200
  • From Sept 2026 to the primary completion date, Dec 2027
  • 7 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • In the investigator's opinion, the participant has concomitant medical condition(s) which could interfere with the study or present a risk to the safety or welfare of the participant or study staff.

Other illness

  • In the investigator's opinion, the participant has a known (or suspected) allergy to medical grade adhesives at enrollment that would interfere with participant completing study required activities.

Lab values

  • Participant is currently in another clinical study which may affect glucose or ketone management (or does so during the study).

Other

  • Participant is unsuitable for participation due to any other cause as determined by the investigator.
  • Participant has implanted medical devices such as pacemakers or requires dialysis or is critically ill.

Who the study is looking for

  • Aged at least 2 years old at the time of study enrollment.
  • Diagnosis of type 1 diabetes with at least 12 months of diabetes medical history.
  • In the investigator's opinion, the participant is willing to wear the sensor, follow study specific instructions, and perform all study tasks.
  • Willing and able to provide written signed and dated informed consent (adults) or participant's parent/legal guardian must be willing and able to provide written signed and dated informed consent along with assent form completed by the participant for those mature enough to make their own decisions per investigator assessment (those less than 16 years of age).

Age in the registry: 2 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (7)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Optimal Clinical Trials
Coordinator of this site? Confirm its status
AucklandNew ZealandUnknown status
New Zealand Clinical Research
Coordinator of this site? Confirm its status
ChristchurchNew ZealandUnknown status
Health New Zealand-Southern
Coordinator of this site? Confirm its status
DunedinNew ZealandUnknown status
Aotearoa Diabetes Collective
Coordinator of this site? Confirm its status
HamiltonNew ZealandUnknown status
Te Pae Hauora o Ruahine o Tararua /MidCentral Health New Zealand
Coordinator of this site? Confirm its status
Palmerston NorthNew ZealandUnknown status
Optimal Clinical Trials (North)
Coordinator of this site? Confirm its status
RosedaleNew ZealandUnknown status
New Zealand Clinical Research
Coordinator of this site? Confirm its status
WellingtonNew ZealandUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.